Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LUCIRA HEALTH, INC.

(LHDX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
6.43(c) 5.98(c) 5.42(c) 5.3(c) 4.9(c) Last
221 819 187 720 241 366 293 886 377 487 Volume
-9.56% -7.00% -9.36% -2.21% -7.55% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 66,3 M - -
Net income 2021 -85,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,57x
Yield 2021 -
Sales 2022 184 M - -
Net income 2022 4,57 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,58x
Yield 2022 -
Capitalization 192 M 192 M -
Capi. / Sales 2021 2,90x
Capi. / Sales 2022 1,05x
Nbr of Employees 102
Free-Float -
More Financials
Company
Lucira Health, Inc. is medical technology company. The Company is focused on the development and commercialization of transformative and infectious disease test kits. The Company has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory... 
More about the company
Ratings of Lucira Health, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LUCIRA HEALTH, INC.
01/11Lucira™ Check-It PCR-Quality, At-Home Molecular COVID-19 Test Now Available in th..
AQ
01/11Lucira Health, Inc. Announces Lucira™ Check-It PCR-Quality
CI
01/10LUCIRA HEALTH : Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021 ..
PU
01/10Lucira Health Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021..
AQ
01/10Lucira Health, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Fu..
CI
01/06SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucir..
PR
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucir..
PR
2021Health Care Stocks Decline Premarket Wednesday
MT
2021Lucira Health Strikes Distribution Agreement for Infectious Disease Test Kits
MT
2021LUCIRA HEALTH : and Co-Defend/Co-Protect Announce Expanded Partnership for 2022 - Form 8-K
PU
2021LUCIRA HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
2021Lucira Health and Co-Defend/Co-Protect Announce Expanded Partnership for 2022
GL
2021Lucira Health and Co-Defend/Co-Protect Announces Expanded Partnership for 2022
CI
2021LUCIRA HEALTH : Regulation FD Disclosure - Form 8-K
PU
2021LUCIRA HEALTH, INC. : Regulation FD Disclosure (form 8-K)
AQ
More news
News in other languages on LUCIRA HEALTH, INC.
01/11Lucira Health, Inc. annonce la qualité PCR Lucira Check-It
01/10Lucira Health, Inc. fournit des prévisions de revenus préliminaires pour le quatrième t..
2021Les actions du secteur de la santé en baisse mercredi avant le marché
2021Lucira Health conclut un accord de distribution de kits de tests pour les maladies infe..
2021Lucira Health et Co-Defend/Co-Protect annoncent un partenariat élargi pour 2022
More news
Analyst Recommendations on LUCIRA HEALTH, INC.
More recommendations
Chart LUCIRA HEALTH, INC.
Duration : Period :
Lucira Health, Inc. Technical Analysis Chart | LHDX | US54948U1051 | MarketScreener
Technical analysis trends LUCIRA HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 4,90 $
Average target price 8,00 $
Spread / Average Target 63,3%
EPS Revisions
Managers and Directors
Erik T. Engelson President, Chief Executive Officer & Director
Daniel George Chief Financial Officer & Treasurer
David A. Lamond Chairman
Debkishore Mitra Director & Chief Technology Officer
Tony Allen Chief Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
LUCIRA HEALTH, INC.-43.09%192
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.5.89%22 461
BIOMÉRIEUX-18.57%13 650
10X GENOMICS, INC.-40.06%9 974
DIASORIN S.P.A.-14.69%8 865
NATERA, INC.-32.82%5 935